Atherectomy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Atherectomy is a minimally invasive endovascular procedure that physically removes or ablates atherosclerotic plaque from within diseased coronary or peripheral arteries using specialised catheter-based devices. Unlike balloon angioplasty (which compresses and displaces plaque) or stenting (which scaffolds the artery open), atherectomy actively debulks the plaque burden within the vessel wall, creating a larger lumen and modifying plaque morphology before or instead of stent placement. The procedure is performed through a puncture in the femoral, radial, or brachial artery, with real-time fluoroscopic and intravascular imaging guidance.

Atherosclerotic plaque — composed of lipid deposits, foam cells, fibrous tissue, and calcified components — accumulates within the intima and media of arteries over decades, driven by hyperlipidaemia, hypertension, diabetes, and smoking. Severely calcified or fibrotic lesions are particularly challenging to dilate with conventional balloon angioplasty, as calcified plaque resists compression and increases the risk of stent underexpansion and restenosis. Atherectomy addresses these complex lesions by removing or modifying the calcium and plaque before final balloon dilation and stenting.

Atherosclerosis is performed by interventional cardiologists (coronary) or interventional radiologists and vascular surgeons (peripheral), typically in a cardiac catheterisation laboratory or vascular suite. Following the procedure, antiplatelet therapy and risk factor modification are central to preventing recurrence.

Coronary atherectomy is indicated for complex coronary artery disease lesions that are heavily calcified, fibrotic, or undilatable — situations where conventional balloon angioplasty would fail to achieve adequate stent expansion, increasing restenosis risk. Rotational atherectomy (rotablation) is the most widely used coronary technique, directed at calcified lesions before drug-eluting stent placement. Orbital atherectomy and laser atherectomy are alternative coronary approaches.

Peripheral atherectomy addresses atherosclerotic occlusions in the femoral-popliteal, infrapopliteal (tibial), and iliac arterial segments in patients with peripheral artery disease (PAD) causing intermittent claudication or critical limb-threatening ischaemia (CLTI). It is particularly valuable for long-segment occlusions, ostial lesions, and the infrapopliteal vessels below the knee where conventional stenting is less optimal. Directional atherectomy (Turbohawk), orbital atherectomy (Diamondback 360), and excimer laser atherectomy are used in the peripheral circulation.

Candidates for coronary atherectomy include patients with angiographically confirmed moderate-to-severely calcified coronary lesions (confirmed on intravascular ultrasound or optical coherence tomography) requiring percutaneous coronary intervention (PCI), where calcium prevents adequate balloon expansion. Clinical presentation may be stable angina refractory to medical therapy or acute coronary syndrome in patients with complex coronary anatomy.

Peripheral atherectomy is appropriate for PAD patients with lifestyle-limiting claudication unresponsive to supervised exercise therapy and medical management, or CLTI patients with rest pain, non-healing ulcers, or gangrene threatening limb viability. Adequate inflow and access vessel anatomy must be confirmed. Contraindications include severely compromised renal function (contrast nephropathy risk), allergy to iodinated contrast (manageable with pre-medication), uncorrectable bleeding disorders, severe coagulopathy, and the absence of adequate target vessel anatomy for catheter delivery.

Rotational atherectomy (rotablation) uses a diamond-tipped burr rotating at 135,000–180,000 rpm to ablate calcified plaque into microparticles smaller than red blood cells, which are cleared by the reticuloendothelial system. It is the dominant coronary atherectomy technique for severely calcified lesions and is typically followed by drug-eluting stent implantation. Orbital atherectomy uses an eccentrically rotating diamond-coated crown to sand calcium through differential speed, achieving larger ablation zones.

For peripheral vascular disease, directional atherectomy (SilverHawk/TurboHawk) uses a rotating cutting blade to shave plaque from the artery wall and pack excised tissue into an onboard collection nosecone, directly removing material from the vessel. Orbital atherectomy (Diamondback 360) is particularly effective for calcified peripheral lesions. Excimer laser atherectomy uses ultraviolet laser energy to vaporise plaque through photomechanical and photochemical mechanisms, useful for in-stent restenosis, thrombus-containing lesions, and undilatable occlusions. Drug-coated balloon technology is frequently used after peripheral atherectomy to reduce restenosis.

Selecting the most appropriate Atherectomy approach requires a structured assessment of patient-specific factors. The treating specialist evaluates disease severity, prior treatment history, comorbidities, and patient preferences before recommending a specific protocol. Combination approaches are often more effective than monotherapy — integrating pharmacological, procedural, or rehabilitative elements to address multiple disease mechanisms simultaneously. Dose or intensity is titrated incrementally based on clinical response, tolerability, and objective outcome measures. In patients with refractory disease or inadequate response to first-line protocols, escalation to higher-intensity or specialist-delivered treatment options is indicated. Multidisciplinary team (MDT) review ensures that surgical, medical, and allied health perspectives are integrated into the final management plan, particularly for complex or high-risk cases where multiple treatment pathways are viable and the risk-benefit balance requires careful deliberation.

Coronary rotational atherectomy in severely calcified lesions enables successful drug-eluting stent implantation with adequate expansion in over 90% of cases, with procedural success rates and 1-year outcomes equivalent to non-calcified lesions treated by conventional PCI. Freedom from major adverse cardiac events (MACE) at 1 year is approximately 85–90% for complex calcified coronary lesions treated with rotablation followed by DES.

Peripheral atherectomy for claudication and CLTI achieves primary patency (freedom from restenosis) of 70–80% at 12 months for femoropopliteal disease when combined with drug-coated balloon therapy, and limb salvage rates of 85–90% at 1 year in CLTI patients with tibial disease. Compared to conventional balloon angioplasty alone for calcified peripheral lesions, atherectomy followed by drug-coated balloon demonstrates superior 1-year primary patency in multiple randomised trials.

Coronary rotational atherectomy carries the risk of coronary slow-flow or no-reflow phenomenon (microparticle embolisation causing transient coronary spasm and ischaemia), occurring in 1–3% of cases and typically responsive to intracoronary vasodilators. Coronary perforation is rare (under 0.5%) but serious, requiring immediate management with covered stents or pericardiocentesis. Burr entrapment requiring emergency surgery has been reported but is extremely rare.

Peripheral atherectomy risks include arterial perforation (1–3%), distal embolisation of excised or disrupted plaque fragments causing acute limb ischaemia (2–5%, managed with aspiration thrombectomy or thrombolysis), access site haematoma, and contrast-induced nephropathy. Restenosis remains the principal medium-term limitation of all atherectomy techniques, requiring surveillance and potential re-intervention. Long-term outcomes are heavily influenced by ongoing cardiovascular risk factor modification.

Risk mitigation strategies are integral to Atherectomy delivery. Pre-treatment optimisation of modifiable risk factors — including blood pressure control, glycaemic management, smoking cessation, and anticoagulation bridging where relevant — substantially reduces peri-procedural complication rates. Patients are monitored closely during and after treatment using standardised clinical protocols, ensuring that emerging adverse events are detected and managed promptly. All serious adverse events are documented and reported within the quality assurance framework of the treating institution.

After coronary atherectomy with stenting, patients are observed for 12–24 hours and discharged the following day. Dual antiplatelet therapy (aspirin plus clopidogrel or ticagrelor) is prescribed for 6–12 months to prevent in-stent thrombosis. Cardiac rehabilitation is recommended following any PCI. Repeat angiography or functional assessment with FFR (fractional flow reserve) is performed at 6–12 months if symptoms recur.

After peripheral atherectomy, hospitalisation is typically 1–2 days with same-day ambulation. Antiplatelet therapy (aspirin plus clopidogrel for 1–3 months, then aspirin monotherapy long-term) is continued. Duplex ultrasound surveillance of the treated segment is performed at 1 month and 6–12 months to monitor for restenosis. Supervised exercise rehabilitation for PAD and comprehensive wound care for CLTI patients are essential components of ongoing management.

Coronary atherectomy in the United States costs between USD 30,000 and USD 70,000 inclusive of catheterisation laboratory, device costs (rotational atherectomy burr system USD 3,000–5,000), surgeon, and hospital fees. Peripheral atherectomy costs USD 20,000–50,000 in the US. Insurance coverage is generally available for clinically indicated procedures in patients with coronary or peripheral artery disease refractory to medical management.

Medical tourists can access coronary or peripheral atherectomy at JCI-accredited cardiac and vascular centres in India for approximately USD 5,000–12,000, in Thailand for USD 10,000–18,000, and in Turkey for USD 8,000–15,000 — savings of 60–80% versus US pricing. High-volume interventional cardiology centres in these countries routinely perform complex calcified coronary and peripheral vascular procedures with outcomes comparable to leading international centres.

Several key factors determine the final cost of Atherectomy: clinical complexity of the individual case, the specific technique or protocol selected, specialist time required, imaging and laboratory testing, implant or device costs where applicable, and the duration of post-treatment monitoring. Geographic location exerts a strong influence — urban tertiary-care centres in high-income countries charge premium rates, while equivalent accredited care in India, Thailand, Turkey, and Mexico provides comparable clinical outcomes at 50–75% lower cost. Patients seeking international treatment should factor in travel, accommodation, and the cost of follow-up care on return home. Private health insurance coverage varies considerably; patients should obtain pre-authorisation in writing and confirm what components of the treatment pathway are included. Many patients access government healthcare subsidies or medical financing plans to spread the cost of elective and semi-elective procedures.

For calcified coronary lesions, intravascular lithotripsy (IVL — Shockwave Medical) represents an emerging alternative that uses acoustic pressure waves to fracture coronary calcium without atherectomy, enabling stent expansion in heavily calcified lesions with a favourable safety profile and growing evidence from the DISRUPT CAD randomised trials.

For peripheral artery disease, supervised exercise therapy for 12 weeks is the first-line treatment for claudication, achieving functional improvements comparable to endovascular intervention in some trial comparisons. Angioplasty with drug-coated balloons without preceding atherectomy is an alternative for non-calcified peripheral lesions. Bypass surgery (femoral-popliteal bypass with vein or synthetic graft) remains the gold standard for long-segment occlusions in good-surgical-risk patients, offering superior long-term patency over endovascular options for complex disease.